All In Biotech

Drug Trial Radar · NCT05180994

Topical Infliximab in Eyes With Penetrating Keratoplasty

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

May 1, 2022

Primary completion

Mar 1, 2027

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fonds de recherche en ophtalmologie de l'Université de Montréal; Maisonneuve-Rosemont Hospital; Niagara Health System; Prism Eye Institute; Ottawa Hospital Research Institute
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Conditions

  • Glaucoma Following Surgery

Interventions

  • Topical infliximabDrug

    Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

  • No topical infliximabOther

    No treatment with infliximab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complications associated to PKP surgeryTime frame: 6 months
  2. Complications associated to infliximab useTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.